Abstract
The management of invasive giant prolactinomas (IGP) has been an area of some controversy. The relative roles of transsphenoidal surgery, craniotomy, radiation therapy and dopamine agonist based medical therapy are gradually becoming clarified.
We report the results of management of 30 patients with IGP. Surgery was the initial therapy in 18 patients and was nearly always followed by adjunctive treatment with radiotherapy and/or bromocriptine. A second group of 12 patients had initial therapy with bromocriptine; 6 had subsequent radiotherapy and only 1 had transsphenoidal surgery.
Outcomes with regard to relief of mass effect, visual improvement, pituitary function and complications of therapy were superior in the bromocriptine treated patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shrivatava RK, Arginteanu MS, King WA, et al. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 2002;97:299–306.
Asano S, Ueki IK, Kirino T. Clinical features and medical treatment of male prolactinomas. Acta Neurochir(Wien) 2001;143(5):465–475.
Molitch ME, Thorner O, Wilson C. Management of prolactinomas. J Clin Endocrinol Metab 1997;82(3):996–1006.
Gokalp HZ, Deda H, Attar A, et al. The neurosurgical management of prolactinomas. J Neurosurg Sci 2000;44:128–132.
Loh KC, Schlossberg AH. Large macroprolactinoma treated with bromocriptine alone. Ann-Acad-Med-Singapore 1996;25:886–889.
Minniti G, Jaffrain-Rea ML, Santoro A, et al. Giant prolactinomas presenting as skull base tumors. Surg Neurol 2002;57:99–104.
Grebe SK, Delahunt JW, Feek CM. Treatment of extensively invasive (giant) prolactinomas with bromocriptine. N Z Med J 1992;105(931):129–131.
Schofl-Siegert B, Brabant G, von zur Muhlen A, et al. Reversible blindness caused by an invasive prolactinoma. Dtsch med Wochenschr 2001;126:621–624.
Sieck JO, Niles NL, Jinkins JR, et al. Extrasellar prolactinomas: successful management of 24 patients using bromocriptine. Horm Res 1986;23:167–176.
Van't Verlaat JW, Croughs RJ, Hendricks MJ, et al. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension. Can J Neurol Sci 1990;17:71–73.
Clayton RN, Webb J, Heath DA, et al. Dramatic and rapid shrinkage of a massive invasive prolactinoma with bromocriptine: a case report. Clin Endocrinol(Oxf) 1985;22:573–581.
Moster ML, Savino PJ, Shatz NJ, et al. Visual function in prolactinoma patients treated with bromocriptine. Ophthalmology 1985;92:1332–1341.
Woodhouse NJ, Khoupueer F, Sieck JO. Prolactinomas and optic nerve compression: disappearance suprasellar extension and visual recovery after two weeks bromocriptine treatment. Horm Res 1981;14:141–147.
Mbanya JC, Mendelow AD, Crawford PJ, et al. Rapid resolution of visual abnormalities with medical therapy alone in patients with large prolactinomas. Br J Neurosurg 1993;7:519–527.
Roux FX, Nataf F, Page P, Devaux B, Brami F. The role of surgery in the treatment of prolactinomas. Gynecol Obstet Fertil 2002;30(5):367–373. Review. French.
Acquati S, Pizzocaro A, Tomei G, et al. A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma. J Neurosurg Sci 2001;45:65–69.
Davis JR, Sheppard MC, Heath DA. Giant invasive prolactinoma; a case report and review of nine further cases. Q J Med 1990;74:227–238.
Saeki N, Nakamura M, Sunami K, et al. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocr J 1998;45(4):529–537.
Author information
Authors and Affiliations
Additional information
Report of 30 cases
Rights and permissions
About this article
Cite this article
Yu, C., Wu, Z. & Gong, J. Combined Treatment of Invasive Giant Prolactinomas. Pituitary 8, 61–65 (2005). https://doi.org/10.1007/s11102-005-5087-0
Issue Date:
DOI: https://doi.org/10.1007/s11102-005-5087-0